Changes in Corneal Epithelial Thickness Induced by Topical Antiglaucoma Medications

Corneal thickness measurement is important for assessing intraocular pressure in patients with glaucoma. This study investigated the changes in corneal epithelial thickness (CET) induced by antiglaucoma medications and explored the factors affecting CET measurement. CET was measured over a 9.0 mm diameter area by using Fourier domain optical coherence tomography in 125 patients with primary open-angle glaucoma and 125 age-matched controls without glaucoma. The influence of sex, age, benzalkonium chloride (BAK)-containing instillations, disease severity, and types and numbers of medications was analyzed using simple and multiple regression analyses. CET over 25 sectors was smaller in the glaucoma group than in the control group (mean difference of 4.2 mu m in the central 2.0 mm zone; 52.8 +/- 3.6 vs. 48.5 +/- 3.9, p < 0.001). Simple regression analysis revealed age, use of beta-blockers, prostaglandin, carbonic anhydrase inhibitors, total number of medications, and number of daily BAK-containing instillations were associated with a thinner epithelium. Multiple regression analysis revealed beta-blockers, prostaglandin, and number of BAK-containing instillations were significant factors. Use of beta-blockers and number of BAK-containing instillations were also associated with a thinner epithelium in the monotherapy subgroup analysis. CET was significantly smaller in patients with glaucoma receiving topical medications and was affected by the use of beta-blockers, prostaglandin, and BAK.

Automated summary

Corneal epithelial thickness (CET) was found to be smaller in patients with glaucoma receiving topical medications compared to controls. Among various factors influencing CET, the use of beta-blockers, prostaglandin, and frequency of BAK-containing instillations were significant.